In 2020 will the maker of a new immunotherapy be willing to give up even more of the value of their new hospital administered cancer treatment through statutory price reductions to fund the cost of distributing old and commoditised generic medicines?
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
